JP5746015B2 - Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 - Google Patents

Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 Download PDF

Info

Publication number
JP5746015B2
JP5746015B2 JP2011504377A JP2011504377A JP5746015B2 JP 5746015 B2 JP5746015 B2 JP 5746015B2 JP 2011504377 A JP2011504377 A JP 2011504377A JP 2011504377 A JP2011504377 A JP 2011504377A JP 5746015 B2 JP5746015 B2 JP 5746015B2
Authority
JP
Japan
Prior art keywords
quinolin
yloxy
phenyl
fluoro
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011504377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517689A (ja
JP2011517689A5 (enExample
Inventor
アクセル ウルリッヒ
アクセル ウルリッヒ
ピョートル クニャゼフ
ピョートル クニャゼフ
イーシャン ジャン
イーシャン ジャン
ケリー ジョルジー
ケリー ジョルジー
ラズロ オルフィ
ラズロ オルフィ
シュトヴァーン サバトカイ
シュトヴァーン サバトカイ
Original Assignee
マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー, マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー filed Critical マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
Publication of JP2011517689A publication Critical patent/JP2011517689A/ja
Publication of JP2011517689A5 publication Critical patent/JP2011517689A5/ja
Application granted granted Critical
Publication of JP5746015B2 publication Critical patent/JP5746015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011504377A 2008-04-16 2009-04-16 Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 Active JP5746015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4539808P 2008-04-16 2008-04-16
US61/045,398 2008-04-16
PCT/EP2009/002798 WO2009127417A1 (en) 2008-04-16 2009-04-16 Quinoline derivatives as axl kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2011517689A JP2011517689A (ja) 2011-06-16
JP2011517689A5 JP2011517689A5 (enExample) 2012-05-31
JP5746015B2 true JP5746015B2 (ja) 2015-07-08

Family

ID=40999731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011504377A Active JP5746015B2 (ja) 2008-04-16 2009-04-16 Ａｘｌキナーゼ阻害剤としてのキノリン誘導体

Country Status (12)

Country Link
US (1) US9206130B2 (enExample)
EP (1) EP2262772B8 (enExample)
JP (1) JP5746015B2 (enExample)
KR (1) KR101325237B1 (enExample)
CN (1) CN102131783A (enExample)
AU (1) AU2009237938A1 (enExample)
CA (1) CA2718538A1 (enExample)
ES (1) ES2391373T3 (enExample)
IL (1) IL208103A (enExample)
MX (1) MX2010011224A (enExample)
RU (1) RU2010146474A (enExample)
WO (1) WO2009127417A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311809A1 (en) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
EP3045453A1 (en) * 2011-11-14 2016-07-20 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
DK2810937T3 (en) 2012-01-31 2017-03-13 Daiichi Sankyo Co Ltd PYRIDONE DERIVATIVES
US20150164800A1 (en) 2012-07-25 2015-06-18 Xetrios Therapeutics, Inc. Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
US9873670B2 (en) 2013-11-22 2018-01-23 University Of Kentucky Research Foundation Arylquinoline and analog compounds and use thereof to treat cancer
EP3074390B1 (en) 2013-11-27 2020-07-08 SignalChem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
ES2749726T3 (es) * 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
ES2896079T3 (es) 2016-02-26 2022-02-23 Ono Pharmaceutical Co Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario
JP7034084B2 (ja) 2016-03-28 2022-03-11 インサイト・コーポレイション Ｔａｍ阻害剤としてのピロロトリアジン化合物
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
HUE054883T2 (hu) 2017-01-26 2021-10-28 Ono Pharmaceutical Co N-{5-[(6,7-dimetoxi-4-kinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-kinolinkarboxamid etánszulfonát sója
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
CA3074013A1 (en) * 2017-08-31 2019-03-07 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
EA202190153A1 (ru) 2018-06-29 2021-04-09 Инсайт Корпорейшн Составы ингибитора axl/mer
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CA3182673A1 (en) * 2020-05-08 2021-11-11 Georgiamune Llc Akt3 modulators
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
HU230789B1 (en) * 1999-01-22 2018-05-02 Kyowa Hakko Kirin Co Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
CA2744997A1 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
EP1919900A2 (de) * 2005-08-22 2008-05-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN101528702A (zh) * 2006-06-08 2009-09-09 阿雷生物药品公司 喹啉化合物和使用方法
CN105106199A (zh) * 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法

Also Published As

Publication number Publication date
KR101325237B1 (ko) 2013-11-04
KR20100132038A (ko) 2010-12-16
WO2009127417A1 (en) 2009-10-22
ES2391373T3 (es) 2012-11-23
US20110092503A1 (en) 2011-04-21
EP2262772A1 (en) 2010-12-22
EP2262772B1 (en) 2012-07-18
EP2262772B8 (en) 2013-03-13
RU2010146474A (ru) 2012-05-27
IL208103A0 (en) 2010-12-30
AU2009237938A1 (en) 2009-10-22
JP2011517689A (ja) 2011-06-16
CA2718538A1 (en) 2009-10-22
MX2010011224A (es) 2011-02-25
IL208103A (en) 2015-08-31
US9206130B2 (en) 2015-12-08
CN102131783A (zh) 2011-07-20

Similar Documents

Publication Publication Date Title
JP5746015B2 (ja) Ａｘｌキナーゼ阻害剤としてのキノリン誘導体
AU2010214095B2 (en) Novel amino azaheterocyclic carboxamides
EP1415987B1 (en) Nitrogenous aromatic ring compounds as anti cancer agents
CN102977014B (zh) 新的喹啉类化合物及其用途
BR112020025869A2 (pt) compostos
CA2909310A1 (en) Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
KR20050034732A (ko) 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산
CN107098846B (zh) N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
NO336275B1 (no) Forbindelse, angitt som quinazolinanalog som reseptor tyrosin kinaseinhibitor, anvendelse derav for fremstilling av et medikament, samt farmasøytisk sammensetning omfattende forbindelsen
CN106478606B (zh) N-取代吲哚类衍生物及其应用
CN107056755B (zh) 五元杂环酰胺类wnt通路抑制剂
US20250136580A1 (en) Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
ES2334708T3 (es) (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht.
CN104876878A (zh) 5-芳基酚-2烷基取代脲苯并咪唑类化合物及其应用
HK1156952A (en) Quinoline derivatives as axl kinase inhibitors
CN105263926B (zh) 苯并噻吩化合物
RU2838187C2 (ru) Соединения
TW202521522A (zh) 用於預防或治療癌症或腫瘤之新穎化合物及包含該化合物的醫藥組成物
CN117343046A (zh) 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
CN102432592A (zh) 具有抗肿瘤作用的芳基脲衍生物及其制备方法
JP2008519085A (ja) アミド誘導体、それらの製造及び医薬品としての使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150507

R150 Certificate of patent or registration of utility model

Ref document number: 5746015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250